| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Necrostatin-7 targets an as yet unknown regulatory molecule in the necroptosis pathway. Unlike other necrostatins that inhibit RIP1 kinase, Necrostatin-7 does not inhibit RIP1 kinase activity. The compound inhibits TNF-α-induced necroptosis in a FADD-deficient variant of human Jurkat T cells. Its mechanism of action is distinct from other necrostatins, making it a valuable tool for dissecting necroptosis signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, Necrostatin-7 inhibits TNF-α-induced necroptosis in a FADD-deficient variant of human Jurkat T cells. It does not inhibit RIP1 kinase. The compound is a potent inhibitor of necroptosis. Its distinct mechanism of action suggests that it may target an unknown regulatory molecule in the pathway. Detailed in vitro data are available in the primary literature. The compound is a valuable tool for studying necroptosis mechanisms.
|
| ln Vivo |
In vivo data for Necrostatin-7 are limited in publicly available sources. Based on its potent necroptosis inhibitory activity, the compound is expected to be useful for in vivo studies of necroptosis in various disease models including ischemic injuries, neurodegeneration, inflammatory diseases, and autoimmune disorders. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic profile.
|
| Enzyme Assay |
In vitro necroptosis assays for Necrostatin-7 typically use FADD-deficient Jurkat T cells or other cell lines. Cells are cultured in RPMI-1640 with 10% FBS. Cells are seeded in 96-well plates and pre-treated with Necrostatin-7 at various concentrations (0.01-10 μM) for 30-60 minutes. Necroptosis is induced by TNF-α (with or without z-VAD-fmk and SMAC mimetic). Cell death is measured by propidium iodide uptake, LDH release, or MTT assay. RIP1 kinase activity is assessed to confirm lack of RIP1 inhibition. All treatments include vehicle controls and are performed in triplicate.
|
| Cell Assay |
For cell-based assays, Jurkat T cells (FADD-deficient variant) are cultured in RPMI-1640 with 10% FBS. Cells are seeded in 96-well plates and pre-treated with Necrostatin-7 at various concentrations (0.01-10 μM) for 30-60 minutes. Necroptosis is induced by TNF-α. Cell death is measured by propidium iodide uptake, LDH release, or MTT assay. RIP1 kinase activity is assessed by Western blotting or kinase assays to confirm lack of RIP1 inhibition. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, Necrostatin-7 may be administered to rodents via intraperitoneal (IP) or intravenous (IV) injection. The compound is formulated in a suitable vehicle such as DMSO, PEG, or saline-based solutions. For disease models (e.g., ischemic injury, neurodegeneration, inflammatory diseases, autoimmune disorders), animals are dosed at various regimens. Endpoints include tissue damage assessment, inflammatory cytokine levels, and survival analysis. Blood and tissue samples are collected for pharmacokinetic and pharmacodynamic analysis. All procedures follow institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Necrostatin-7 (MW 371.41, C₁₆H₁₀FN₅OS₂) is a potent inhibitor of necroptosis. The compound shows a purity of ≥98%. It does not inhibit RIP1 kinase. Detailed pharmacokinetic parameters are not extensively reported in publicly available sources. The compound is typically stored at -20°C. Further ADME studies are needed to fully characterize its pharmacokinetic profile. The compound is a crystalline solid.
|
| Toxicity/Toxicokinetics |
Toxicology data for Necrostatin-7 are limited in publicly available sources. As a necroptosis inhibitor, potential effects on cell death pathways should be considered. The compound is for research use only and not intended for human therapeutic applications. Standard safety pharmacology and toxicology studies would be required for therapeutic development. The compound should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
Necrostatin-7 is a research-grade necroptosis inhibitor for studying cell death pathways. Its primary applications include cell death research, immunology, and drug discovery. The compound is not approved for clinical use and has not entered clinical trials. It is commercially available from various chemical suppliers for research purposes only. Its mechanism involves inhibition of TNF-α-induced necroptosis through an unknown target distinct from RIP1 kinase.
|
| Molecular Formula |
C16H10FN5OS2
|
|---|---|
| Molecular Weight |
371.4
|
| Exact Mass |
371.031
|
| CAS # |
351062-08-3
|
| PubChem CID |
1239801
|
| Appearance |
Light yellow to brown solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
613.4±65.0 °C at 760 mmHg
|
| Flash Point |
324.8±34.3 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.805
|
| LogP |
2.73
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
581
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1C2=C(C=NN2)/C=C\3/C(=O)N(C(=N)S3)C4=NC=CS4)F
|
| InChi Key |
SMJGLNVGTJLIRV-KBEFMPHXSA-N
|
| InChi Code |
InChI=1S/C16H10FN5OS2/c17-11-3-1-9(2-4-11)13-10(8-20-21-13)7-12-14(23)22(15(18)25-12)16-19-5-6-24-16/h1-8,18H,(H,20,21)/b12-7-,18-15?
|
| Chemical Name |
(5Z)-5-[[5-(4-fluorophenyl)-1H-pyrazol-4-yl]methylidene]-2-imino-3-(1,3-thiazol-2-yl)-1,3-thiazolidin-4-one
|
| Synonyms |
Necrostatin7 Necrostatin 7 Necrostatin-7
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6925 mL | 13.4626 mL | 26.9251 mL | |
| 5 mM | 0.5385 mL | 2.6925 mL | 5.3850 mL | |
| 10 mM | 0.2693 mL | 1.3463 mL | 2.6925 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
